|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 瑞武美尼>> 市场分析报告 |
瑞武美尼市场分析报告 |
|
Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 ... most promising candidates currently. Revumenib was developed by Syndax Pharmaceuticals ... -101 clinical trials is assessing Revumenib as a monotherapy in acute leukemias and ... -102 clinical trial is testing Revumenib in combination with chemotherapy to determine ... Global Menin Inhibitors Drug Market, Price, Sales & Clinical Trials Insight 2028 ... with the October 2024 approval of revumenib (Revuforj) for KMT2A-rearranged AML ... Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies), By Region, and Competition, 2020-2030F ... U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor ... |